MA30604B1 - Agonistes de ep2 - Google Patents

Agonistes de ep2

Info

Publication number
MA30604B1
MA30604B1 MA31593A MA31593A MA30604B1 MA 30604 B1 MA30604 B1 MA 30604B1 MA 31593 A MA31593 A MA 31593A MA 31593 A MA31593 A MA 31593A MA 30604 B1 MA30604 B1 MA 30604B1
Authority
MA
Morocco
Prior art keywords
agonists
methods
compositions
glaucoma
treating
Prior art date
Application number
MA31593A
Other languages
English (en)
Inventor
Ganesh Prasanna
Charles Floyd Bosworth
Fontaine Jennifer Anne La
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA30604B1 publication Critical patent/MA30604B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES AGONISTES DE EP2, DES PROCÉDÉS POUR LEUR PRÉPARATION, DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES COMPOSÉS, ET DES PROCÉDÉS D'UTILISATION DE CES COMPOSÉS ET COMPOSITIONS POUR ABAISSER LA PRESSION INTRA-OCULAIRE ET AINSI TRAITER UN GLAUCOME.
MA31593A 2006-07-28 2009-01-28 Agonistes de ep2 MA30604B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US94192307P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
MA30604B1 true MA30604B1 (fr) 2009-07-01

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31593A MA30604B1 (fr) 2006-07-28 2009-01-28 Agonistes de ep2

Country Status (25)

Country Link
US (2) US7622475B2 (fr)
EP (1) EP2059507B1 (fr)
JP (1) JP4583500B2 (fr)
KR (1) KR101088942B1 (fr)
AP (1) AP2009004754A0 (fr)
AR (1) AR062122A1 (fr)
AU (1) AU2007280130B2 (fr)
BR (1) BRPI0714683A2 (fr)
CA (1) CA2659184C (fr)
CL (1) CL2007002207A1 (fr)
CR (1) CR10554A (fr)
EA (1) EA200970067A1 (fr)
EC (1) ECSP099071A (fr)
GT (1) GT200700064A (fr)
IL (1) IL196355A0 (fr)
MA (1) MA30604B1 (fr)
MX (1) MX2009001062A (fr)
NO (1) NO20090738L (fr)
NZ (1) NZ573964A (fr)
PE (1) PE20080408A1 (fr)
RS (1) RS20090002A (fr)
TN (1) TN2009000028A1 (fr)
TW (1) TWI372757B (fr)
UY (1) UY30511A1 (fr)
WO (1) WO2008015517A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201904655T4 (tr) 2008-03-12 2019-06-21 Ube Industries Piridilaminoasetik asit bileşiği.
KR101681347B1 (ko) 2009-03-30 2016-11-30 우베 고산 가부시키가이샤 녹내장의 치료 또는 예방을 위한 의약 조성물
US20120226036A1 (en) * 2009-09-11 2012-09-06 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030871A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés hétéroaryle n-substitués
WO2011030864A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés aniline
WO2011030872A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés sulfonamide
WO2011030873A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques
WO2011030865A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques substitués
JPWO2011078303A1 (ja) * 2009-12-25 2013-05-09 宇部興産株式会社 アミノピリジン化合物
BR112013003600A2 (pt) * 2010-08-17 2016-08-16 Allergan Inc agonistas ep2 ou ep4 para o tratamento de névoa da córnea
JP2014530177A (ja) 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
HK1210969A1 (en) * 2012-01-20 2016-05-13 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
JP6120951B2 (ja) 2012-05-03 2017-04-26 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 新規ｅｐ２受容体作動薬
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
AU2014244926A1 (en) 2013-03-28 2015-11-12 Ube Industries, Ltd. Substituted biaryl compound
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
AR105215A1 (es) * 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico
AU2017225999B2 (en) 2016-03-04 2022-08-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
CA3065945A1 (fr) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procedes pour prevenir ou traiter des affections musculaires

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (fr) * 1998-06-23 2002-07-24 Pfizer Products Inc. Méthode de traitement du glaucome
EP1108426A3 (fr) 1999-12-02 2002-10-02 Pfizer Products Inc. Utilisation d'agonistes des prostaglandines pour traiter les troubles de l'érection et l'impotence
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
KR20040063981A (ko) 2001-11-30 2004-07-15 화이자 프로덕츠 인크. Ｅｐ2 수용체 선택성 작용제를 포함하는 제약 조성물 및투여 방법
PY0300568A (es) * 2002-01-31 2004-10-01 Pfizer Prod Inc Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
JP2006519250A (ja) 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるｅｐ２選択的受容体アゴニストの使用
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Also Published As

Publication number Publication date
CR10554A (es) 2009-02-10
WO2008015517A3 (fr) 2008-06-12
RS20090002A (sr) 2010-06-30
AR062122A1 (es) 2008-10-15
EA200970067A1 (ru) 2009-08-28
UY30511A1 (es) 2008-02-29
KR101088942B1 (ko) 2011-12-01
PE20080408A1 (es) 2008-04-28
HK1133876A1 (en) 2010-04-09
JP4583500B2 (ja) 2010-11-17
MX2009001062A (es) 2009-02-06
ECSP099071A (es) 2009-02-27
KR20090023507A (ko) 2009-03-04
TWI372757B (en) 2012-09-21
AU2007280130A1 (en) 2008-02-07
CA2659184C (fr) 2012-02-21
WO2008015517A2 (fr) 2008-02-07
GT200700064A (es) 2009-06-18
BRPI0714683A2 (pt) 2013-03-26
EP2059507B1 (fr) 2013-03-20
NO20090738L (no) 2009-04-27
CA2659184A1 (fr) 2008-02-07
AU2007280130B2 (en) 2011-09-22
EP2059507A2 (fr) 2009-05-20
TW200817360A (en) 2008-04-16
US20100105905A1 (en) 2010-04-29
TN2009000028A1 (fr) 2010-08-19
AP2009004754A0 (en) 2009-02-28
CL2007002207A1 (es) 2008-02-01
JP2009544751A (ja) 2009-12-17
NZ573964A (en) 2010-11-26
IL196355A0 (en) 2009-09-22
US20080045545A1 (en) 2008-02-21
US7622475B2 (en) 2009-11-24

Similar Documents

Publication Publication Date Title
TN2009000028A1 (fr) Agonistes de ep2
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
WO2008056259A3 (fr) Dérivés d'oxazole utilisés en tant que modulateurs allostériques positifs des récepteurs métabotropiques du glutamate
MA30765B1 (fr) Derives innovants du thiophene
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
TW200621722A (en) 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
WO2008007211A8 (fr) Composés de carboxyamide bicycliques à n-bicycloalkyle substitué
MA26965A1 (fr) Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
MY145074A (en) Thiazolidin-4-one derivatives
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
MA32506B1 (fr) Nouveaux composes
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide